Roma. Neutralizing antibodies against SARS-CoV-2 in most cases lasts at least 8 months after infection in patients who develop them, according to a study released today by San Rafael Hospital in Milan and the Italian Institute of Healthcare (ISS).
Infections that produce antibodies in the first fifteen days are less likely to be affected by severe symptoms of Covit-19, the study published in the scientific journal Nature Communications on Tuesday.
The duration of antibodies and their early importance in combating infection are two key findings of research conducted by the San Rafael Hospital and the San Rafael Diabetes Research Institute on Viral Evolution and Dissemination and the San Rafael Diabetes Research Institute. Goblal Health Center and ISS Department of Infectious Diseases.
From the follow-up of 162 SARS-CoV-2 positive patients with various symptoms, research concludes that antibodies remain in the body for at least 8 months, regardless of the severity of the disease, the age or presence of the patient. Previous pathology.
The first blood samples taken were similar to those of March and April 2020, the last being taken in November.
“Eight months after the diagnosis, only three patients showed no positive (antibody) test,” ISS and San Rafael explained in a statement today.
In the first two weeks after the onset of symptoms, 79% of people produced antibodies that were not at high risk for serious illness, regardless of other factors.
“Patients who are unable to develop neutralizing antibodies in the first week of infection should be identified and treated in a timely manner as there is a higher risk of developing severe forms of the disease,” said the director of the hospital’s viral evolution and spread unit. , Gabriella Scarlatti, as stated in the note.
Scarlatti added that the study “has implications for the clinical management of the patient’s disease and the likelihood of infection.”
The study also analyzed the reactivation of antibodies against seasonal corona viruses that caused the winter, and concluded that they “partially recognize the new corona virus and may reactivate after infection, although they are not effective in neutralizing it”.
However, this is good news because it is feared that the proliferation of these types of antibodies will reduce the production of specific for SARS-CoV-2 and have adverse effects on the course of the infection.